bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board
November 10 2022 - 8:15AM
Business Wire
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced
Sheila Habib, MD, Director of Pulmonary Lung Nodule Clinic and the
Lung Cancer Screening Program at the South Texas Veterans Health
Care Systems’ Audie L. Murphy Memorial Veterans Hospital, and David
Hill, MD, National Board Member of the American Lung Association
and assistant clinical professor of medicine at Yale University
School of Medicine, have joined the Company’s Scientific and
Medical Advisory Board.
“Dr. Habib and Dr. Hill will join other members of our
Scientific and Medical Advisory Board who provide independent
expert advice and counsel on the Company’s research and development
of innovative cancer diagnostics, including CyPath® Lung, a
non-invasive test for the early detection of lung cancer,”
bioAffinity President and CEO Maria Zannes said. “The caliber of
the physicians and researchers who accepted our invitation to join
our Scientific and Medical Advisory Board will accelerate the work
of our own scientists to bring breakthrough technology to the early
diagnosis of cancer.”
“Dr. Hill and Dr. Habib will join other recognized leaders in
the lung cancer field who are deeply involved in screening and
early diagnosis when treatment options offer the best potential
outcome,” said bioAffinity’s Chief Science and Medical Officer and
Executive Vice President, Vivienne Rebel, MD, PhD. “We believe
their groundbreaking work complements our mission to provide
innovative products that have the potential to save thousands of
lives every year.”
“Studies show that lung and bronchus cancers represent 20% of
all cancers among our veteran population,” said Dr. Habib who is
also an Assistant Professor at the University of Texas Health
Science Center at San Antonio who specializes in pulmonary nodule
management and lung cancer. “We also know that lung cancer is
difficult to detect in its early stages and by the time our
patients are symptomatic, treatment options are not as effective. A
non-invasive, highly accurate and relatively low-cost assay like
CyPath can change the paradigm for the diagnosis and treatment of
lung cancer not just for veterans but for all patients.”
"bioAffinity's test using fluorescence technology is a unique
approach which can lead to earlier lung cancer diagnosis with
better outcomes, while avoiding the morbidity and mortality of
invasively evaluating non-cancerous lesions," said Dr. Hill, who is
director of clinical research at Waterbury Pulmonary Associates in
addition to his positions at Yale and the American Lung
Association. “The goal of screening is to identify lung cancers
early when treatment can be curative, but most lung cancers are
currently identified at a late stage when they become symptomatic
and the prognosis of this disease is extremely poor.
"Currently, low-dose CT scans are indicated for lung cancer
screening in a select group of patients with heavy smoking
histories," Dr. Hill said. "Unfortunately, these CT scans have a
relatively high false-positive rate with small nodules of uncertain
etiology and behavior being identified."
CyPath® Lung is a non-invasive test that has shown 92%
sensitivity and 87% specificity in detecting early-stage lung
cancer in individuals at high risk for the disease who have lung
nodules less than 20mm. The test is intended for use by physicians
for patients who display a pulmonary nodule requiring
follow-up.
Drs. Habib and Hill join Science and Medical Advisory Board
members Neil Alexis, PhD, Catherine Sears, MD, and Gerard
Silvestri, MD.
- Neil Alexis, PhD, Principal Investigator at the University of
North Carolina School of Medicine Center for Environmental
Medicine, Asthma and Lung Biology. Dr. Alexis focuses on the use of
sputum as a primary sampling tool for measuring cellular,
biochemical and genetic outcomes in the human airway. Dr. Alexis is
a leading expert in the use of flow cytometry in the analysis of
sputum.
- Catherine Sears, MD, Assistant Professor of Medicine at Indiana
University School of Medicine. Dr. Sears is a physician scientist
whose laboratory focuses on the impact of DNA damage and repair on
the development of smoking-related lung cancers and on treatment
response. She co-chairs the pulmonary oncology and lung cancer
screening programs at the Indianapolis VA Medical Center and her
clinical and research interests focus on improving lung cancer
screening and early lung cancer detection and treatment.
- Gerard Silvestri, MD, MS, FCCP, Professor of Medicine and Lung
Cancer Pulmonologist at the Medical University of South Carolina.
Dr. Silvestri specializes in the evaluation, management and
improvement of outcomes in lung cancer patients. He has experience
in evaluating new technologies for the diagnosis and staging of
lung cancer. His research includes screening for lung cancer, how
patients should be diagnosed and staged with the disease, and how
to evaluate new technologies needed to diagnose and treat these
patients.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses
the need for noninvasive diagnosis of early-stage cancer and
diseases of the lung, and targeted cancer treatment. The Company’s
first product, CyPath® Lung, is a non-invasive test that has shown
high sensitivity and specificity for the detection of early-stage
lung cancer. Precision Pathology Services licensed and developed
CyPath® Lung as a Laboratory Developed Test (LDT) and has begun
test marketing in Southeast Texas. OncoSelect® Therapeutics, LLC, a
subsidiary of bioAffinity Technologies, is advancing its
discoveries shown in vitro to kill cancer cells without harm to
normal cells. Research and optimization of the Company’s platform
technologies are conducted in its laboratories at The University of
Texas at San Antonio.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding the anticipated use of proceeds from
the Company’s offering of common shares. Forward-looking statements
can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar
expressions, or the negative of these words. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221110005448/en/
Company Contact: Maria Zannes, President & Chief
Executive Officer mz@bioaffinitytech.com
Investor Relations Contact: Tiberend Strategic Advisors,
Inc. Jonathan Nugent jnugent@tiberend.com or David Irish
dirish@tiberend.com
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Mar 2024 to Apr 2024
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Apr 2023 to Apr 2024